Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer

Journal of B.U.ON.

Volumn 15, Issue 3, 2010, Pages 462-469

  Oztop, Ilhan ^a   Alacacioglu, A ^b   Unek, I T ^a   Tarhan, O ^c   Somali, I ^c   Cokmert, S ^d   Yavuzsen, T ^a   Yilmaz, U ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Izmir Ataturk Training and Research Hospital   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d ANTAKYA STATE HOSPITAL   (Turkey)

Author keywords

5 fluorouracil; Advanced stage; Gemcitabine; Pancreatic cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 77957732417     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics. CA Cancer J Clin 2006; 56: 106-130.
2. Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615. (Pubitemid 47041235)
3. Hawes R, Xiong Q, Waxman I et al. A multispeciality approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 2000; 95: 17-31.
4. Burris H, Moore M, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomised trial. J Clin Oncol 1997; 15: 2403-2413.
5. Riess H, Helm A, Niedergethmann M et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23 (Suppl): 310s (abstr LBA4009).
6. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952.
7. Stathopoulos GP, Syrigos K, Aravantinos G et al. A multi-center phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95: 587-592. (Pubitemid 44325898)
8. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
9. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine-oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24 (Suppl): 180s (abstr LBA4004).
10. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
11. Ishikawa T, Utoh M, Sawada N et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55: 1091-1097.
12. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
13. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217. (Pubitemid 46954645)
14. Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005; 27: 23-44.
15. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 14: 808-815. (Pubitemid 27074252)
16. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
17. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
18. Oztop I, Yilmaz U, Yaren A et al. Gemcitabine combined with infusional 5-fluorouracil and high dose leucovorin for the treatment of advanced carcinoma of pancreas. Chemotherapy 2004; 50: 127-132.
19. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review. Cancer 1996; 78: 633-638.
20. Xinopoulos D, Dimitroulopoulos D, Karanikas I et al. Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial. J BUON 2008; 13: 341-347.
21. Fung M, Takayama S, Ishiguro H et al. Chemotherapy for advanced or metastatic pancreatic cancer: Analysis of 43 randomised trials in 3 decades (1974-2002). Gan To Kagaku Ryoho 2003; 30: 1101-1111.
22. Polyzos A, Tsavaris N, Vafiadis I et al. Phase II study of gemcitabine plus 5-fluorouracil biologically modulated by folinic acid plus long-acting formulation of octreotide (LAR) in patients with advanced pancreatic cancer. J BUON 2005; 10: 357-364. (Pubitemid 41404162)
23. Oettle H, Arning M, Pelzer U et al. A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol 2000; 11: 1267-1272.
24. Louvet C, Andre T, Hammel P. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001; 12: 675-679.
25. Gurzler F, Moehler M, Hosch WP et al. A phase I study of gemcitabine (GEM) in combination, with five days 5-fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct. Proc Am Soc Clin Oncol 1999; 18: A1097 (abstr).
26. Marantz A, Jovtis S, Almira E et al. Phase II trial of gemcitabine, 5-fluorouracil and leucovorin in patients with pancreatic cancer. Semin Oncol 2001; 28: 44-49.
27. Castellano D, Paz-Ares L, Pronk L et al. A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing of administration of gemcitabine (G) and folinic acid (FA)/fluorouracil (FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 2000; 19: A1133 (abstr).
28. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
29. Rauch DP, Maurer Ca, Aebi S et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology 2001; 60: 43-48. (Pubitemid 32041430)
30. Anchisi S, Delaloye B, Petite J et al. Gemcitabine (Gem) and continuous infusion 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: A1280H (abstr).
31. Cascinu S, Silva RR, Barni S et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1999; 80: 1595-1598. (Pubitemid 29308642)
32. Berlin JD, Adak S, Vaughn DJ et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology 2000; 58: 215-218.
33. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
34. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-219. (Pubitemid 127774295)
35. Heinemann V, Labianca R, Hinke A et al. Superiority of gemcitabine plus platinum analog compared to gemcitabine alone in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter study. ASCO Gastrointestinal Cancers Symposium Program/Proceedings 2006 (abstr no. 96).
36. Ahn SH, Garewal HS, Dragovich T. Discrepancy in the assessment of tumor response in patients with pancreatic cancer: WHO versus RECIST criteria. J BUON 2008; 13: 359-362.
37. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
38. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002; 94: 902-910.
39. Cascinu S, Labianca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients - A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14: 205-208. (Pubitemid 36305430)
40. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
41. Philip PA, Zalupski MM, Vaitkevicius VK et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569-577.
42. Gennatas C, Michalaki V, Mouratidou D et al. Gemcitabine combined with 5-fluorouracil for the treatment of advanced carcinoma of the pancreas. In Vivo 2006; 20: 301-305.
43. Andra T, Noirclerc M, Hamel P et al. Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). Gastroenterol Clin Biol 2004; 28: 645-650.